Other Events ·
Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders' votes…
ARQTArcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 5, 2026, where stockholders' votes on three proposals, including the election of Class III directors (Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe), the ratification of andhesion to Ernst & Young LLP as independent auditor, and a voting on a non-binding advisory basis of executive officer compensation. The Board of Directors approved revisions to the Amended and Restated Non-Employee Director Compensation Program, Board members are compensated with annual cash and equity compensation. Arcutis Biotherapeutics, Inc. is a biopharmaceutical company that develops and commercializes commercial-stage products for inflammatory and inflammatory-related skin diseases.